315 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Kelly
    Kelly
  4. Gerecitano
    Gerecitano
  5. O'Reilly
    O'Reilly
  6. Slovin
    Slovin
  7. Smart-Curley
    Smart-Curley
  8. Morris
    Morris
  9. Schwartz
    Schwartz
  10. Zelenetz
    Zelenetz

Groups

  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)
  7. Biostatistics Service (45)
  8. Survivorship Research (45)
  9. Radiology, Department of (42)
  10. Nursing (41)
  1. "hyperglycemia"
Formats
  1. Journal Article (294)
  2. Review (17)
  3. Guidelines (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (223)
  2. Solid Tumor Oncology Division (164)
  3. Hematologic Malignancies, Division of (77)
  4. Genitourinary Oncology Service (67)
  5. Center for Hematologic Malignancies (53)
  6. Epidemiology and Biostatistics (47)

More Groups

People
  1. Robert Motzer (28)
  2. Howard Scher (15)
  3. William Kelly (14)
  4. Eileen O'Reilly (11)
  5. John Gerecitano (11)
  6. Susan Slovin (11)

More People

Years
  1. 2025 (8)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (9)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (27)
  2. Clinical Cancer Research (20)
  3. Cancer (14)
  4. Lancet Oncology (14)
  5. Annals of Oncology (12)
  6. Investigational New Drugs (12)

More Publications

Publishers
  1. Elsevier Inc. (42)
  2. Springer (32)
  3. American Society of Clinical Oncology (28)
  4. Elsevier Science, Inc. (23)
  5. Oxford University Press (23)
  6. American Association for Cancer Research (21)

More Publishers

Results (315)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA
    Journal Article

    Hochhaus, A.; Kim, D. W.; Cortes, J. E.; Sasaki, K.; Mauro, M. J.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
    Journal Article

    Rugo, H. S.; Bardia, A.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Jhaveri, K.; Mahtani, R.; Tolaney, S. M.
    Breast (2025)

    Fulltext@MSK | Save
  • Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
    Journal Article

    Bedard, P. L.; Jhaveri, K. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    European Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: Analysis of key subgroups of the MAIA study
    Journal Article

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Understanding oncologic emergencies and related emergency department visits and hospitalizations: A systematic review
    Journal Article

    Yilmaz, S.; Aryal, K.; King, J.; Bischof, J. J.; Hong, A. S.; Wood, N.; Gould Rothberg, B. E.; Hudson, M. F.; Heinert, S. W.; Wattana, M. K.; more...
    BMC Emergency Medicine (2025)

    Fulltext@MSK | Save
  • SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
    Journal Article

    Shroff, R. T.; King, G.; Colby, S.; Scott, A. J.; Borad, M. J.; Goff, L.; Matin, K.; Mahipal, A.; Kalyan, A.; Javle, M. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S. L.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Leptin signaling maintains autonomic stability during severe influenza infection in mice
    Research Letter

    Muñoz-Rojas, A. R.; Wang, A. C.; Pomeranz, L. E.; Reizis, E. L.; Stout-Delgado, H. W.; Miranda, I. C.; Rajagopalan, K.; Gwatiringa, T.; Fan, R. R.; Huda, A. A.; more...
    Journal of Clinical Investigation (2025)

    Fulltext@MSK | Save
  • Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer
    Journal Article

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Sunpaweravong, P.; Musolino, A.; more...
    New England Journal of Medicine (2024)

    Fulltext@MSK | Save